|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Adenosine#Use in Specific Populations]] |
| {{Adenosine}}
| |
| {{CMG}}; {{AE}} {{AZ}}
| |
| | |
| ===Pregnancy Category C===
| |
| Animal reproduction studies have not been conducted with adenosine; nor have studies been performed in pregnant women. As adenosine is a naturally occurring material, widely dispersed throughout the body, no fetal effects would be anticipated. However, since it is not known whether Adenocard can cause fetal harm when administered to pregnant women, Adenocard should be used during pregnancy only if clearly needed.
| |
| | |
| ===Pediatric Use===
| |
| No controlled studies have been conducted in pediatric patients to establish the safety and efficacy of Adenocard for the conversion of [[paroxysmal supraventricular tachycardia]] (PSVT). However, intravenous adenosine has been used for the treatment of PSVT in neonates, infants, children and adolescents (see Dosage and Administration).
| |
| | |
| ===Geriatric Use===
| |
| Clinical studies of Adenocard did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, Adenocard in geriatric patients should be used with caution since this population may have a diminished cardiac function, nodal dysfunction, concomitant diseases or drug therapy that may alter hemodynamic function and produce severe bradycardia or AV block.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ADENOCARD (ADENOSINE) SOLUTION [ASTELLAS PHARMA US, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f0e32589-dad9-4887-8481-bcf7f6618466 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Drugs]]
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Drugs]]
| |
| [[Category:Antiarrhythmic agents]]
| |